CSIR to begin clinical trial of drugs favipiravir, phytopharmaceutical for Covid-19 treatment
- The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs – ‘favipiravir’ and ‘phytopharmaceutical’ – to combat coronavirus.
ABOUT FAVIPRAVIR (T-705)
- It is a drug which is commonly used in Japan, China and some other countries.
- It is sold under the brand name Avigan.
- It is used to treat influenza that has a very broad spectrum of RNA polymerase.
- It is derived from Pyrazinamide that is frequently used against West Nile virus, Arenavirus or Bunyavirus, and Yellow fever etc.
- It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014.
- In 2016, Fujifilm licensed API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
- The clinical trial of Favipiravir is to be completed in about one and half months.
- If the tests are successful, the drugs are to be available at affordable rate.
- It is essentially herbal medicine extracted from plants.
- It is already being tested as medicine for dengue for its efficacy to combat COVID-19.
- It comprises of various bio-active compounds that are used for diagnosis, treatment, mitigation, or prevention of any disease or disorder in human beings.
- The Food and Drug Administration (FDA) terms it botanical in the US, however in India the DCGI refers it as
- In May 2016, a renowned pharmaceutical company and International Centre for Genetic Engineering and Biotechnology (ICGEB), Delhi, had signed an agreement to develop a botanical drug for treatment against dengue.
- Largest research and development organisation
- Director General-Shekhar Mande
- Location-New Delhi